The following IPOs are expected to price this week:
BioAmber (BIOA), which converts renewable feedstocks into bio-succinic acid and other chemicals, plans to raise $128 million by offering 8.0 million shares at a price range of $15.00 to $17.00. At the midpoint of the proposed range, BioAmber would command a market value of $325 million. BioAmber, which was founded in 2008, booked $2 million in sales over the last 12 months. The Montreal, Canada-based company plans to list on the NYSE under the symbol BIOA. Credit Suisse, Societe Generale and Barclays are the joint bookrunners on the deal.
Ellington Residential Mortgage REIT (EARN), a mortgage REIT that invests in Agency RMBS and non-Agency RMBS, plans to raise $129 million by offering 6.5 million shares at a price range of $20.00 to $20.00. At the midpoint of the proposed range, Ellington Residential Mortgage REIT would command a market value of $183 million. Ellington Residential Mortgage REIT, which was founded in 2012, booked $0 million in sales over the last 12 months. The Old Greenwich, CT-based company plans to list on the NYSE under the symbol EARN. Credit Suisse, Deutsche Bank, Citi and UBS Investment Bank are the joint bookrunners on the deal.
GW Pharmaceuticals (GWPH), which develops and commercializes cannabinoid-based therapeutics, plans to raise $38 million by offering 3.5 million shares at a price range of $10.79 to $10.79. At the midpoint of the proposed range, GW Pharmaceuticals would command a market value of $208 million. GW Pharmaceuticals, which was founded in 1998, booked $50 million in sales over the last 12 months. The Wilshire, United Kingdom-based company plans to list on the NASDAQ under the symbol GWPH. Lazard Capital Markets, Cowen & Company and Canaccord Genuity are the joint bookrunners on the deal.
ING U.S. (VOYA), ING's US retirement, insurance and investment management business, plans to raise $1.4 billion by offering 64.2 million shares at a price range of $21.00 to $24.00. At the midpoint of the proposed range, ING U.S. would command a market value of $5.8 billion. ING U.S., which was founded in 1999, booked $9.6 billion in sales over the last 12 months. The New York, NY-based company plans to list on the NYSE under the symbol VOYA. Morgan Stanley, Goldman Sachs, Citi and BofA Merrill Lynch are the joint bookrunners on the deal.
Insys Therapeutics (INSY), a commercial stage pharma with products for breakthrough cancer pain and CINV, plans to raise $68 million by offering 4.0 million shares at a price range of $16.00 to $18.00. At the midpoint of the proposed range, Insys Therapeutics would command a market value of $287 million. Insys Therapeutics, which was founded in 1990, booked $15 million in sales over the last 12 months. The Phoenix, AZ-based company plans to list on the NASDAQ under the symbol INSY. Wells Fargo Securities and JMP Securities are the joint bookrunners on the deal.
QIWI (QIWI), which provides payment services in Russia through kiosks and mobile wallets, plans to raise $204 million by offering 12.0 million shares at a price range of $16.00 to $18.00. At the midpoint of the proposed range, QIWI would command a market value of $891 million. QIWI, which was founded in 2004, booked $282 million in sales over the last 12 months. The Nicosia, Cyprus-based company plans to list on the NASDAQ under the symbol QIWI. J.P. Morgan and Credit Suisse are the joint bookrunners on the deal.
Renaissance Capital will have Pre-IPO Research available on each of these upcoming IPOs prior to its pricing.
